Filing Details

Accession Number:
0000950170-24-030309
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-12 20:01:29
Reporting Period:
2024-03-09
Accepted Time:
2024-03-12 20:01:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1341235 Aldeyra Therapeutics Inc. ALDX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1579179 C Todd Brady C/O Aldeyra Therapeutics, Inc.
131 Hartwell Avenue
Lexington MA 02421
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-03-11 97,914 $3.27 1,556,622 No 4 S Direct
Common Stock Disposition 2024-03-12 85,324 $3.05 1,471,298 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2024-03-09 1,081,201 $0.00 1,081,201 $3.62
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,081,201 2034-03-08 No 4 A Direct
Footnotes
  1. These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards.
  2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.35. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.11. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024.